This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents

Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents
Reviewed by Sofia Rokerya

2 August 2022 | Sofia Rokerya | EYE - Vitreo-Retinal | Aflibercept, Anti-vascular endothelial growth factor, Bevacizumab, Endophthalmitis, Filling, Prefilled syringe, Ranibizumab, Syringe
Share This

In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents – bevacizumab, ranibizumab, and aflibercept. There were four types of the syringe-filling technique – prefilling by a hospital pharmacy, prefilling by a good manufacturing practice (GMP) pharmacy, self-drawing from the vial by the injecting physician, and use of a prefilled syringe. One hundred and forty-three thousand, three hundred and eighteen (72.6%) received bevacizumab injections, 28,906 (14.6%) ranibizumab injections, and 25,178 (12.8%) aflibercept injections respectively. The indications for intravitreal injections included age-related macular degeneration in 39 (73.6%) cases, diabetic macular oedema in six (11.3%) cases, retinal vascular occlusions in six (11.3%) cases, and other diseases in two (3.8%) cases. A total of 53 cases of post-injection endophthalmitis occurred. These included 31 (58.4%) women and 22 (41.6%) men, with a mean age of 75.2 ±12.2 years (range 33-97 years). Patients who suffered from endophthalmitis underwent 11.1 ±12.3 previous intravitreal injections (range 1-34). There was no correlation between number of previous injections nor age with the occurrence of endophthalmitis. Mean follow-up from presentation with endophthalmitis was 20.2 ±17.6 months. 29 (54.7%) cases following bevacizumab injections, 10 (18.9%) cases following ranibizumab injections, and 14 (26.4%) cases following aflibercept injections. The overall risk of post-injection endophthalmitis was 0.027% (1:3,725). The overall risk of post-injection endophthalmitis was 0.027% (1:3,725). The rate of post-injection endophthalmitis was 0.02% (1:4,942) with bevacizumab, 0.34% (1:2,892) with ranibizumab, and 0.055% (1:1,798) with aflibercept. The rate of endophthalmitis following aflibercept injections was significantly higher than that following bevacizumab injections (p = 0.001). There was no statistically significant difference between the rates of endophthalmitis following aflibercept and ranibizumab injections (p = 0.24) nor between the rates of endophthalmitis following bevacizumab and ranibizumab injections (p = 0.13). Of the bevacizumab injections, 31,627 were prefilled by a hospital pharmacy and 111,691 were prefilled by a GMP pharmacy. There were six cases of endophthalmitis following bevacizumab injections prefilled by a hospital pharmacy (0.019%, or 1:5,271) and 23 cases following bevacizumab injections prefilled by a GMP pharmacy (0.02%, or 1:4,856), with no significant difference between these rates (p = 0.85). Of the ranibizumab injections, 14,729 were drawn by the injecting physician and 14,177 were performed with a prefilled syringe. Of the 10 endophthalmitis cases, eight occurred in the self-drawn injections (0.054%, or 1:1,841) and two following the use of prefilled syringes (0.014%, or 1:7,238). There was also no difference in the rates of positive cultures between the different anti-VEGF agents (p = 0.39) or time periods (p = 0.76). A trend was noted toward a lower rate of endophthalmitis with prefilled syringes (0.019% verses 0.055%, p < 0.0001). The authors recommend the use of pre-filled syringes as these may be timesaving and help improve safety reduce infections. Limitations: Retrospective nature, no standardisation of injection techniques, as administered by numerous physicians with different levels of expertise. Strengths: Large multicentre study including all three available Anti-VEGFs.

The Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents.
Finkelstein M, Katz G, Zur D, Rubowitz A.
OPHTHALMOLOGICA
2022;245:34-40.
Share This
Sofia Rokerya
CONTRIBUTOR
Sofia Rokerya

MBBS MRCOphth FRCSI, King's College University Hospital, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency